In the following years, inhibitors with higher specificity toward specific mutant RAF isoforms were developed, e.g. vemurafenib, dabrafenib, or encorafenib, which target and inhibit mutant BRAFV600E/V600K proteins in melanoma (123). This evidence concerns the gene RAF1 and melanoma.